The product, NovoSeven RT, can be stored at room  temperature for up to two years, the Food and Drug  Administration said. An older formulation had to be  refrigerated. NovoSeven RT is a genetically engineered version of Factor  VIIa, a protein found in plasma that is essential for the  clotting of blood. Approved uses of NovoSeven RT include treatment of  bleeding, and prevention of surgical bleeding, in certain  patients with hemophilia. The most commonly observed reactions with NovoSeven RT  include fever, bleeding, injection site reactions, joint  discomfort, headaches, and elevations or falls in blood  pressure, the FDA said. Some elderly patients had an increased risk of arterial  clots when treated with NovoSeven RT for unapproved uses, the  FDA added.
U.S. clears new version of Novo Nordisk clot therapy.